JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Authors
Keywords
-
Journal
Nature Reviews Gastroenterology & Hepatology
Volume 17, Issue 6, Pages 323-337
Publisher
Springer Science and Business Media LLC
Online
2020-03-19
DOI
10.1038/s41575-020-0273-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension study
- (2019) Julián Panés et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice
- (2019) Graham J. Britton et al. IMMUNITY
- Defining Dysbiosis in Inflammatory Bowel Disease
- (2019) Renske J. de Jong et al. IMMUNITY
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
- (2019) Tamara Pérez-Jeldres et al. Frontiers in Pharmacology
- Correction of Defective T-Regulatory Cells From Patients With Crohn’s Disease by Ex Vivo Ligation of Retinoic Acid Receptor-α
- (2019) Rimma Goldberg et al. GASTROENTEROLOGY
- P041 THE GUT-SELECTIVE, ORALLY ADMINISTERED, PAN-JAK INHIBITOR TD-1473 DEMONSTRATES FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETIC, AND SIGNAL FOR CLINICAL ACTIVITY IN SUBJECTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Pharmacology, efficacy and safety of JAK inhibitors in Crohn’s disease
- (2019) Christopher Ma et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
- (2019) Christopher Ma et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- SARI attenuates colon inflammation by promoting STAT1 degradation in intestinal epithelial cells
- (2019) Lei Dai et al. Mucosal Immunology
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
- (2019) Christopher Andrew Lamb et al. GUT
- Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
- (2019) Qiuyao Huang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial
- (2018) Arnab Mukherjee et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
- (2018) F. Valenzuela et al. BRITISH JOURNAL OF DERMATOLOGY
- Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders
- (2018) Robert P. Hirten et al. Clinical Gastroenterology and Hepatology
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2018) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
- (2018) Uma Mahadevan et al. INFLAMMATORY BOWEL DISEASES
- P601 Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study
- (2018) R Panaccione et al. Journal of Crohns & Colitis
- P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study
- (2018) J Panes et al. Journal of Crohns & Colitis
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
- (2018) Jenny D. Beebe et al. PHARMACOLOGY & THERAPEUTICS
- Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
- (2018) Xavier Mariette et al. ARTHRITIS CARE & RESEARCH
- Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease
- (2018) James Kinchen et al. CELL
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
- (2018) Stephen Hanauer et al. Clinical Gastroenterology and Hepatology
- Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment
- (2018) Moses Kasembeli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients
- (2018) Rishi J. Desai et al. Arthritis & Rheumatology
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- STA-21, a STAT-3 inhibitor, attenuates the development and progression of inflammation in collagen antibody-induced arthritis
- (2017) Sheikh Fayaz Ahmad et al. IMMUNOBIOLOGY
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- P469 Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects
- (2017) B. Ferslew et al. Journal of Crohns & Colitis
- A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
- (2017) Misato Ito et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Fine-mapping inflammatory bowel disease loci to single-variant resolution
- (2017) Hailiang Huang et al. NATURE
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Common Cytokine Receptor γ Chain Family of Cytokines
- (2017) Jian-Xin Lin et al. Cold Spring Harbor Perspectives in Biology
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model
- (2016) A. C. Gavino et al. ALLERGY
- Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
- (2016) M. Xiang et al. BLOOD
- Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
- (2016) Seiichi Odate et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
- (2016) Mohamed-Eslam F. Mohamed et al. CLINICAL PHARMACOKINETICS
- STAT3 signaling in immunity
- (2016) Emily J. Hillmer et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
- (2016) Megan E. B. Clowse et al. DRUG SAFETY
- Next generation of small molecules in inflammatory bowel disease
- (2016) Pablo Olivera et al. GUT
- Perianal Crohnʼs Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway
- (2016) Manreet Kaur et al. INFLAMMATORY BOWEL DISEASES
- The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD)
- (2016) Olga F. Sarmento et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
- (2016) Fernando Gomollón et al. Journal of Crohns & Colitis
- JAK2Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages
- (2016) Matija Hedl et al. JOURNAL OF IMMUNOLOGY
- Signaling via the CytoR/JAK/STAT/SOCS pathway: Emergence during evolution
- (2016) Clifford Liongue et al. MOLECULAR IMMUNOLOGY
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
- (2015) Florence Namour et al. CLINICAL PHARMACOKINETICS
- Interleukin-12: Functional activities and implications for disease
- (2015) Sebastian Zundler et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
- (2015) Brian Bressler et al. GASTROENTEROLOGY
- Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
- (2015) Walter Reinisch et al. GUT
- The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD
- (2015) J Cosín-Roger et al. Mucosal Immunology
- Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
- (2015) Jimmy Z Liu et al. NATURE GENETICS
- The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation
- (2015) Dan Lu et al. NATURE IMMUNOLOGY
- Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis
- (2015) Stacey N. Harbour et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- Activated STAT5 Confers Resistance to Intestinal Injury by Increasing Intestinal Stem Cell Proliferation and Regeneration
- (2015) Shila Gilbert et al. Stem Cell Reports
- THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects
- (2014) J. Voss et al. ANNALS OF THE RHEUMATIC DISEASES
- Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
- (2014) Silvio Danese et al. GUT
- Human Lymphoid Development in the Absence of Common -Chain Receptor Signaling
- (2014) L. A. Kohn et al. JOURNAL OF IMMUNOLOGY
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- A major population of mucosal memory CD4+ T cells, coexpressing IL-18Rα and DR3, display innate lymphocyte functionality
- (2014) P Holmkvist et al. Mucosal Immunology
- Increased Th17-Inducing Activity of CD14+ CD163low Myeloid Cells in Intestinal Lamina Propria of Patients With Crohn’s Disease
- (2013) Takayuki Ogino et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Role of Janus Kinase 3 in Mucosal Differentiation and Predisposition to Colitis
- (2013) Jayshree Mishra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- STAT6 Deficiency Ameliorates Severity of Oxazolone Colitis by Decreasing Expression of Claudin-2 and Th2-Inducing Cytokines
- (2013) M. J. Rosen et al. JOURNAL OF IMMUNOLOGY
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Unknown
- (2013) Yi Li et al. MOLECULAR MEDICINE
- Therapeutic modulators of STAT signalling for human diseases
- (2013) Gabriella Miklossy et al. NATURE REVIEWS DRUG DISCOVERY
- Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s Disease
- (2013) Francesca Zorzi et al. PLoS One
- Common and specific signatures of gene expression and protein–protein interactions in autoimmune diseases
- (2012) T Tuller et al. GENES AND IMMUNITY
- Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations
- (2012) Núria Planell et al. GUT
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Selective Sequestration of STAT1 in the Cytoplasm via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis
- (2012) X. Wu et al. JOURNAL OF IMMUNOLOGY
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
- (2012) Luke Jostins et al. NATURE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanism of interleukin-2-induced mucosal homeostasis
- (2011) Jayshree Mishra et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells
- (2011) L. Lin et al. CANCER RESEARCH
- STAT6 activation in ulcerative colitis: A new target for prevention of IL-13-induced colon epithelial cell dysfunction
- (2011) Michael J. Rosen et al. INFLAMMATORY BOWEL DISEASES
- A Novel Role for Interleukin-27 (IL-27) as Mediator of Intestinal Epithelial Barrier Protection Mediated via Differential Signal Transducer and Activator of Transcription (STAT) Protein Signaling and Induction of Antibacterial and Anti-inflammatory Proteins
- (2011) Julia Diegelmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-γ and IL-17A production
- (2011) Reiko Takahashi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The incidence of gastrointestinal perforations among rheumatoid arthritis patients
- (2010) Jeffrey R. Curtis et al. ARTHRITIS AND RHEUMATISM
- Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis
- (2010) Lydia Durant et al. IMMUNITY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory Lymphocytes and Intestinal Inflammation
- (2009) Ana Izcue et al. Annual Review of Immunology
- Intestinal Effector T Cells in Health and Disease
- (2009) Craig L. Maynard et al. IMMUNITY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Interleukin-19 protects mice from innate-mediated colonic inflammation
- (2009) Yasu-Taka Azuma et al. INFLAMMATORY BOWEL DISEASES
- Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation
- (2009) Melanie A. Kleinschek et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease
- (2009) A. Andoh et al. JOURNAL OF IMMUNOLOGY
- Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment
- (2009) Ingrid Arijs et al. PLoS One
- Hyaluronan-Mediated Leukocyte Adhesion and Dextran Sulfate Sodium-Induced Colitis Are Attenuated in the Absence of Signal Transducer and Activator of Transcription 1
- (2008) Sudip K. Bandyopadhyay et al. AMERICAN JOURNAL OF PATHOLOGY
- Regulation of intestinal barrier function by signal transducer and activator of transcription 5b
- (2008) X Han et al. GUT
- The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease
- (2008) Megan E. Himmel et al. IMMUNOLOGY
- IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells
- (2008) Valérie Dardalhon et al. NATURE IMMUNOLOGY
- Inteferons pen the JAK–STAT pathway
- (2008) Christian Schindler et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Role of STAT3 in inflammatory bowel disease
- (2008) Ken Sugimoto WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now